


## KM91104

Cat. No.:	HY-135474		
CAS No.:	304481-60-5		
Molecular Formula:	C <sub>14</sub> H <sub>12</sub> N <sub>2</sub> O <sub>4</sub>		
Molecular Weight:	272.26		
Target:	Proton Pump		
Pathway:	Membrane Transporter/Ion Channel		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 100 mg/mL (367.30 mM; Need ultrasonic)

Concentration	Solvent	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	3.6730 mL	18.3648 mL	36.7296 mL
	5 mM	0.7346 mL	3.6730 mL	7.3459 mL
	10 mM	0.3673 mL	1.8365 mL	3.6730 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

KM91104, a cell-permeable V-ATPase inhibitor, specifically targets the a3-b2 subunits of V-ATPase<sup>[1]</sup>.

### REFERENCES

[1]. Marrone G, et al. The adenosine monophosphate-activated protein kinase-vacuolar adenosine triphosphatase-pH axis: A key regulator of the profibrogenic phenotype of human hepatic stellate cells. *Hepatology*. 2018;68(3):1140-1153.

---

[2]. Göttle P, et al. Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination. *Glia*. 2019;67(1):160-170. doi:10.1002/glia.23535

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA